Home General Health AstraZeneca Vaccine, benefits and risks in younger people

AstraZeneca Vaccine, benefits and risks in younger people

126
0
AstraZeneca, Vaccine, benefits, risks, younger, thrombosis, thrombocytopenia, Oxford, Covid-19, Eurosurveillance, Vaxzevria, European Medical Agency, EMA
AstraZeneca Vaccine, benefits and risks in younger people

The risk of dying from thrombosis and thrombocytopenia in the under 55 age group using the Oxford – AstraZeneca vaccine is HIGHER than the risk of dying from Covid-19 according to a European Government approved analysis.

A new Eurosurveillance study (1) from the European Centre for Disease Control  reviews the benefits and risks of Vaxzevria, the AstraZeneca Covid 19 vaccine. The study modeled existing data from France, as typical pf European vaccination status.

On 7 April 2021, the European Medical Agency (EMA) concluded that a causal relationship existed between vaccination with Vaxzevria and adverse events of thrombosis in combination with thrombocytopenia (TTS) was a reasonable possibility.

To quote from the report, “In all distribution strategies, the number of COVID-19 deaths averted with the use of Vaxzevria in individuals 55 years and older was substantially higher than the expected number of deaths from TTS in that age group. For instance, using Vaxzevria in those 55 years and older would avert 355 deaths in this group while causing three deaths from TTS”.

“When Vaxzevria was used in younger age groups, the benefit–risk balance was no longer as favourable and even reversed in the younger age groups. For instance, using Vaxzevria in the entire adult population would avert four COVID-19 deaths in the 18–29 year-olds and six in the 30–39 year-olds, but it would be associated with 12 and nine deaths from TTS in these age groups, respectively.

Similar concerns were expressed by Norway and Denmark and have been covered previously.

Reference

  1. Full Report – Benefits and risks associated with different users of the Covid-19 Vaxzevria – https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.26.2100533